Introduction
============

Major depression is a debilitating psychiatric disorder. Of all disability and premature loss of life in developing countries, depression accounts for 3.4% in women and 1.3% in men ([@b6-ndt-3-919]; [@b7-ndt-3-919]) and depression is the most common mental health problem in the elderly. Major depression is found in 1.7% of the elderly population, while pervasive depression is found in 13.4% of the elderly population ([@b3-ndt-3-919]).

Depression in the elderly has a considerable impact on their well-being and level of disability ([@b5-ndt-3-919]Late-life depression may be due to a variety of factors including a longstanding vulnerability, severe stress, and vascular risk. However, depression in the elderly may be more difficult to treat than in other populations. Antidepressants can be administered as a first line treatment; however, this can be problematic, as older patients often cannot tolerate dosages high enough to produce an antidepressant response. Predicting the antidepressant effect and side-effects of pharmacological treatment in the elderly can also be difficult due to the variation in bioavailability. Increasing the duration of antidepressant treatment to up to 12 weeks in order to get a clinical response is also suggested for treatment of depression in the elderly population. However, this approach may be difficult, especially in cases of severe depression. Antidepressant class switching and augmentation with lithium is another treatment option. However, this can also be problematic due to intolerable side-effects or potential adverse reactions with non-psychotropic medications ([@b3-ndt-3-919]). Electroconvulsive therapy (ECT) is a treatment often used to treat depression in the elderly. Although ECT is quite effective and fast acting, it is associated with cognitive and other side-effects including nausea, headache and muscle aches ([@b8-ndt-3-919]). In addition, due to the risks associated with anesthetic use in the elderly ECT is not always a viable option.

Repetitive transcranial magnetic stimulation (rTMS) may be another option in the treatment of late-life depression. Recently, two reviews of the evidence for the efficacy of rTMS as a treatment of depression were completed; they focused mainly on sham-controlled studies, literature reviews, and meta-analysis. These separate reviews indicate that there is statistical evidence that rTMS is more effective than sham treatment, despite the small degree of clinical improvement ([@b24-ndt-3-919]; [@b30-ndt-3-919]). The review by [@b30-ndt-3-919] also stated that rTMS treatment "is a relatively safe and well-tolerated technique with generally minor adverse effects such as localized scalp pain, headache and neck pain".

There have only been a few studies examining the use of rTMS as an antidepressant treatment in elderly patients, for a brief review see [Table 1](#t1-ndt-3-919){ref-type="table"}. [@b10-ndt-3-919] treated a large group of adult patients and demonstrated that overall 42% of patients responded to rTMS. However, only 23% of the elderly patients in the study responded to treatment, suggesting increased efficacy of rTMS in younger populations as compared to elderly. The authors found the rTMS treatments to be well-tolerated in all patients. However, another recent study by [@b9-ndt-3-919] on the effects of rTMS in vascular depression reported that 5 out of 11 patients showed a clinically meaningful improvement in Hamilton Depression Rating Scale scores (HDRS) ([@b18-ndt-3-919]).

Another study ([@b25-ndt-3-919]) found no significant change in HDRS ([@b18-ndt-3-919]) scores before and after rTMS treatment in depressed elderly. They also reported 3 responders out of 10 subjects in the active treatment group and 3 responders out of 10 in the sham treatment group. These finding were attributed to insufficient stimulation parameters. Similarly, a more recent study of rTMS as add-on treatment for depression in the elderly reported no additional antide-pressant effects of real stimulation versus sham treatment. It was also reported that treatment with rTMS was safe, as adverse events were rare and the cognitive assessment demonstrated no deterioration in cognitive function ([@b27-ndt-3-919]).

In contrast to ECT, the benefits of rTMS include efficiency, cost-effective administration on an outpatient basis in contrast to ECT, no need for anesthesia, no seizure induction and a lack of significant cognitive side effects. rTMS may, therefore, be another viable option for the treatment of late-life depression. However, the lack of consensus regarding the antidepressant effects of rTMS in an elderly population indicate there is a need for further research in this area.

The aim of this study is to establish the efficacy and tolerance of repetitive transcranial magnetic stimulation (rTMS) for treatment of older patients with depressive disorders not responding to psychotropic medication.

Materials and methods
=====================

Subjects
--------

Patients were recruited from the population served by a specialized service for mood disorders (both in and out-patients were included). A local ethics board approved the study and only patients who were able to provide written informed consent were included.

Inclusion criteria were: DSM-IV ([@b1-ndt-3-919]) criteria for depressive disorder, unipolar or bipolar type with a HDRS score of ⩾18; 60 years of age or older and willing and capable of continuing with the same medications through out the trial. Diagnosis was confirmed by experienced psychiatrists on the basis of an unstructured clinical interview using the DSM-IV checklist ([@b1-ndt-3-919]).

Exclusion criteria included: Personal or family history of epilepsy or seizure disorder, mass brain lesion, metal in the skull or brain, history of a head trauma, patients who were actively suicidal, with a concurrent serious medical illness, history of alcohol or drug abuse in the last 3 months.

All patients had failed to respond to treatment with at least two adequate trials of at least 6-weeks duration, with an antidepressant. All patients were required to be on stable medications for 6 weeks prior to commencing in the study. They continued taking the maximum tolerated dose of the last antidepressant throughout the two weeks of treatment with rTMS and throughout follow-up. All other psychotropic medications were to remain unchanged for the same period unless readjustments were clinically indicated.

Outcome measures

1.  Mood assessment was performed using the HDRS-21 item, Hamilton Anxiety Rating Scale (HARS) ([@b19-ndt-3-919]) and the Beck Depression Inventory-II (BDI) ([@b4-ndt-3-919]).

2.  Visual Analogue Scale (VAS) for depression (-D), anxiety (-A) and physical discomfort (-PD).

3.  The Clinical Global Impression (CGI) was completed as an additional scale in monitoring response to treatment.

4.  The Mini-Mental Status Exam (MMSE) ([@b13-ndt-3-919]).

The outcome measures (HDRS, HARS, BDI, MMSE, and CGI) were administered at baseline (before rTMS treatment), mid-treatment (after 5 treatments), at the end of treatment (after 10 treatments), two weeks and 1 month after the completion of rTMS. The VAS-D, VAS-A, and VAS-PD were administered after each rTMS session, two weeks and 1 month after the completion of rTMS treatment.

rTMS procedure
--------------

Patients received 10 rTMS sessions over a two-week period with all sessions employing the same stimulation parameters. A Dantec high-speed magnetic stimulator was used. A figure-8 coil was placed over the left dorsolateral prefrontal cortex (DLPFC) defined as a site 5 cm anterior to the site for optimal stimulation of the abductor pollicis brevis (APB) muscle of the contralateral side. The rTMS intensity was set at 100% of the motor threshold and 20 trains of 10 Hz stimulation with a train duration of 8 seconds were delivered at an intertrain interval of 52 seconds.

Results
=======

Twenty patients were enrolled in the study, of these 19 patients completed all 10 rTMS treatments. One patient completed 8 of the 10 treatments but was unable to continue due to local discomfort and headache. Several of the remaining patients developed slight transient discomfort with the first treatment, but none had severe or persistent pain. Of the 20 patients, 6 (30%) were male and 14 (70%) were female, 3 (15%) suffered from bipolar depression and 17 (85%) suffered from unipolar depression. The average age was 66.8 (± 6.4) years and ranged from 60--80 years old. Fifteen patients were assessed at the 2-week follow-up and thirteen were assessed at the 1-month follow-up visit.

There was a significant decrease in the mean HDRS score for the entire population from baseline 25.3 SD 5.8 to 17.3 SD 6.5 after 10 treatments, p = 0.0003. There was a 31.6% mean reduction in HDRS from baseline. The mean HDRS score 1 month after the completion of treatment was found to be 16.6 (SD 8.7), a 34.3% mean reduction from baseline ([Table 2](#t2-ndt-3-919){ref-type="table"}).

After 10 treatments 6 patients showed a reduction in HDRS scores of at least 50% and another patient showed a reduction of at least 50% at the 1-month follow-up visit. Two of the 6 patients also reached remission (defined as a HDRS score \<8). The patient who showed the reduction of 50% at the 1 month follow up visit also reached remission at the 1 month follow up visit.

The mean HARS score at baseline was 19.3 (±8.2) and it reduced to 13.2 (±10.1) after 10 treatments. This is a 31.6% mean reduction from baseline. The mean HARS score 1 month after the completion of treatment was found to be 13.7 (±7.5), a 29.0% mean reduction from baseline ([Figure 1](#f1-ndt-3-919){ref-type="fig"}).

Both HDRS and HARS scores showed a significant decrease at the end of treatment (visit 10) from baseline (p= 0.0003 and p = 0.03, respectively).

As shown in [Table 2](#t2-ndt-3-919){ref-type="table"}, both the BDI and the CGI decreased significantly at the end of treatment from baseline (p = 0.0396 and p = 0.0088, respectively). The VAS for depression and anxiety did not show a significant change (p = 0.117 and p = 0.053, respectively) with treatment. The VAS for physical discomfort did not show a significant increase from baseline to the end of treatment (p = 0.336). Also the MMSE did not show a significant change from baseline to the end of treatment (p = 0.586).

Discussion
==========

This study assessed the effect of rTMS applied to the left dorsal prefrontal cortex as an add-on treatment in medication-resistant depressed patients who were 60 years of age or older. After two weeks (10 rTMS treatments), 30% (6 out of 20 patients) met response criteria (\>50% improvement in HDRS), with two of these patients also meeting criteria for remission (HDRS ⩽ 8).

This finding compares favorably with that of [@b28-ndt-3-919] who used distance adjusted TMS treatments in patients 65--75 years of age. In their study rTMS was administered for 3 weeks to the DLPFC using a stimulation intensity of 114% of the motor threshold (MT) as compared to 2 weeks at 100% of MT in our study. In Nahas et al 28% (5 of 18 subjects) met criteria for response; four of these five patients had exit HDRS scores ⩽ 8, and thus met criteria for remission. Although, our results show a higher number of responders to rTMS, Nahas's study reported a higher number of remitters. The results of our study demonstrate a 31.6% mean reduction in HDRS scores from baseline to the end of study, increasing to 34.3% at one month follow up. Similarly, Nahas et al reported a 35.2% drop on the 28-item HDRS from baseline. Finally, the same authors reported that 10 out of 18 subjects were very much improved or much improved according to the CGI. In our study, CGI demonstrated much or very much improvement in six patients.

[@b27-ndt-3-919] treated elderly depressed patients (mean age = 62 years) with 10 daily rTMS treatments at 100% of motor threshold, similar to our stimulation parameters, and reported a 20% reduction in HDRS-21 scores in the active treatment group. Interestingly, the sham treated group showed a 17% reduction in HDRS. In the Mosimann study, 26.6% (4 of 24) of patients receiving real TMS were responders, similar to the results of our study.

Previous studies found no deterioration in cognitive function in rTMS-treated subjects ([@b26-ndt-3-919]; [@b32-ndt-3-919]). In our study there was no evidence of cognitive deterioration, as MMSE scores remained unchanged throughout the study. However, more rigorous cognitive

[@b27-ndt-3-919] found rTMS to be a safe treatment with none of the patients withdrawing from the study or reporting serious adverse effects. One patient in our study withdrew, after 8 sessions, because of discomfort and headaches.

This is similar to the study by [@b33-ndt-3-919] where 3 out of 30 patients dropped out of the treatment because of pain or worsening of clinical symptoms. As well, four patients in the active and two patients in the sham group reported headaches, which is consistent with complaints reported by our study subjects.

The response rate obtained by most other studies are quite similar to our data, although in contrast to [@b33-ndt-3-919] who found no responder in patients older than 55 years of age. In our study we did not find any significant difference in age, sex, or degree of cognitive impairment between responders and non-responders. In addition, responders and non-responders did not differ in severity of depression, as measured by initial HDRS scores or number of previous antidepressant treatments.

It has yet to be established if rTMS's antidepressant response rates differ between elderly and younger populations of patients with depression. Published reports indicate a lower antidepressant effect of rTMS in elderly depressed patients as compared to younger populations ([@b10-ndt-3-919]; [@b29-ndt-3-919]; [@b33-ndt-3-919]). [@b14-ndt-3-919] found age and treatment refractoriness to be significant negative predictors of depression improvement. They reported that TMS antidepressant therapy in younger and less treatment resistant patients resulted in better outcomes. The findings in our study of a response rate of 31.6% after only 10 daily sessions of rTMS at 100% of MT is comparable to the response rates of 30% and 35% respectively reported by [@b15-ndt-3-919] and [@b11-ndt-3-919] in younger adults.

Two more recent studies reported similar response rates after treating younger adults at higher intensities and for longer sessions. Response rate of 30% was reported by [@b20-ndt-3-919] who gave 4 weeks of high frequency rTMS; and [@b2-ndt-3-919] found a 32% response rate when rTMS was administered for 15 sessions at an intensity of 110% of MT. Although, we administered rTMS for 10 sessions at an intensity of 100% MT, it appears that our older patients responded well.

[@b31-ndt-3-919], who reported a response rate of 61%, argued that treatment response was unrelated to the demographic and clinical characteristics of their patients. [@b12-ndt-3-919] have also reported no relationship between age and response to rTMS treatment. In addition, it is of interest to note that [@b22-ndt-3-919] reported that reduction of depression symptoms in rTMS treated post stroke patients was not influenced by the patient's age or type or location of ischemic strokes.

The limitations of this study require some consideration. This is non-controlled, open study with a small sample size. This is a significant limitation, which likely restricted the statistical power. Our patients all received antidepressants during the trial. We ensured that all patients stayed on a stable dose of the current medications for at least six weeks before commencement of rTMS, during the trial and follow-up period. However, changes to psychotropic medications (excluding antidepressants) were allowed, throughout the study, where clinically indicated. Since the study lacks a control group we cannot exclude the possibility of a placebo effect. The response to rTMS seen in our study may be due to a placebo effect of a cutting edge treatment, but given that all of our subjects had been taking stable doses of the same medication for at least six weeks, were not improving before the trial and had a high degree of resistance, this is unlikely. [@b23-ndt-3-919] reported that more severely depressed patients responded poorly to placebo compared to antidepressant treated subjects.

Recently, it has been suggested that 10 treatments and 100% of MT may not be sufficient to produce a maximum response. But our study was planned and started a few years ago when routine rTMS treatment was a course given for two weeks. Thus, administration of a fixed number (10) of rTMS sessions may have reduced the efficacy of our treatment as a higher number of sessions optimized the clinical benefit of treatment as demonstrated in some recent studies ([@b21-ndt-3-919]; [@b17-ndt-3-919]; [@b31-ndt-3-919]). However the literature is lacking a study that directly compares the effects of 2 different numbers of pulses per day on mood. More rTMS sessions even at higher stimulation intensity have not consistently produced better clinical outcome as reported in newer studies ([@b20-ndt-3-919]; [@b2-ndt-3-919]). [@b31-ndt-3-919] suggested that methodological factors might be responsible for the variable results reported in the literature.

In conclusion, rTMS is a safe and well-tolerated treatment and may be a useful adjunctive treatment to medications in elderly treatment resistant depressed patients. We believe our findings add to the growing body of literature that suggests the effectiveness of rTMS. Despite the fact that the generalizabilty of our study findings are limited, rTMS treatment in older depressed population is showing encouraging results and requires further study.

![HDRS and HARS scores at baseline, mid-treatment, end of treatment, 2 week follow-up and 1 month follow-up. tests are needed to confirm the absence of deterioration in cognitive functioning.](ndt-3-919f1){#f1-ndt-3-919}

###### 

Previous findings of rTMS effect on depression in elderly populations

  Authors            N    Age range          Number of sessions   \% MT            Hz          Response/outcome
  ------------------ ---- ------------------ -------------------- ---------------- ----------- ----------------------------------------------------------------------
  [@b10-ndt-3-919]   50   22--89 (mean 60)   5                    110              10          23% responded to Tx. Well-tolerated
  [@b25-ndt-3-919]   20   60.7 ± 9.8         5                    80               20          No significant change in HDRS scores with Tx
  [@b27-ndt-3-919]   24   62 ± 12            10                   100              20          No addn'l antidepressant effects vs sham
  [@b9-ndt-3-919]    11   67.9 ± 6.7         10                   100              10          5 patients had clinically meaningful improvement in HDRS scores
  [@b29-ndt-3-919]   18   51.2 ± 16          5                    90               0.3 or 10   19% decline in HDRS score for slow rTMS and 6% decline for fast rTMS
  [@b28-ndt-3-919]   18   61.2 ± 7.3         15                   114 (103--141)   5           35% decline over 3 weeks in HDRS score
  [@b16-ndt-3-919]   20   58.4 ± 15.7        20                   90               10          27% decline over 4 weeks in HDRS score

###### 

BDI, VAS-D, -A, -PD, CGI, MMSE scores at baseline, mid-treatment and 1 month follow-up

                         Baseline      End of treatment                                           1 month follow-up
  ---------------------- ------------- ---------------------------------------------------------- -------------------
  BDI                    31.8 ± 9.0    25.0 ± 13.3 [\*\*](#tfn2-ndt-3-919){ref-type="table-fn"}   24.2 ± 13.6
  Visual Analog Scale                                                                             
   Depression            64.5 ± 23.3   52.2 ± 28.9                                                55.5 ± 38.5
   Anxiety               66.3 ± 25.6   48.7 ± 29.5                                                40.8 ± 39.2
   Physical discomfort   24.6 ± 25.8   20.8 ± 26.4                                                36.4 ± 31.7
  CGI                    4.7 ± 0.7     3.9 ± 1.1[\*\*](#tfn2-ndt-3-919){ref-type="table-fn"}      3.1 ± 1.3
  MMSE                   28.2 ± 2.3    29.1 ± 1.5                                                 28.8 ± 1.7

Values presented as mean ± SD.

Significant decrease from baseline.
